Cluster of Differentiation 47 (CD47)

Where the papers sit

11 papers from the last 6 months study Cluster of Differentiation 47 (CD47) directly · updated from PubMed 12 Oct 2026

• Tumor-Associated Macrophage Immunotherapy

  CD47 blockade is moving beyond monotherapy toward combinations that activate or reprogram tumor-associated macrophages. CDK4/6 inhibition and imiquimod are reported to strengthen antitumor effects, while ferumoxytol is linked to macrophage activation and imaging response. Glycocalyx degradation and disulfide-redox remodeling offer additional ways to expose tumor cells to immunity. Osteosarcoma burden remains a constraint, with larger tumors showing weaker macrophage activation and response.

  6 papers · 54.5%

• Vascular CD47 Signaling

  CD47-related vascular signaling is being examined in both tumor vascular mimicry and immune resilience. In triple-negative breast cancer, axitinib disrupts the THBS1-CD47 axis but is associated with increased stemness and vasculogenic mimicry. A separate longevity study links a BPIFB4-platelet-CD47 axis to immune resilience. The shared focus is vascular and immune regulation, while therapeutic implications remain unresolved.

  2 papers · 18.2%

• Others — CD47 Translational Evidence

  Clinical and mechanistic evidence ranges from magrolimab plus azacitidine in higher-risk myelodysplastic syndromes to CD47-related protection in pancreatitis. The clinical study emphasizes response, survival, placebo comparisons, and treatment risk, while kaempferol is linked to altered CD47 signaling and reduced oxeiptosis. A separate machine-learning study addresses a four-gene signature for abdominal aortic aneurysm rather than a CD47-directed therapy. These findings share translational relevance but do not establish one disease-specific direction.

  3 papers · 27.3%